




Minimising hypoglycaemia risk in type 2 diabetes Achieving optimal glycaemic control is fundamental to the effective management of type 2 diabetes (T2D). Hypoglycaemia is one of the major limiting factors to achieving T2D control.

Hypoglycaemia due to glucose-lowering treatments for T2D can adversely affect a person's quality of life, medication adherence and treatment satisfaction, but there are steps healthcare professionals can take to minimise risk and positively impact the patient's health.



Tight glucose control^{1,2} of mild/moderate hypoglycaemia can be as high as

Negative effects of hypoglycaemia



Quality of life¹ and health status⁵



Cognitive² function and mood¹

Physical symptoms include:⁶ headaches, sweating, shakiness, weakness, lack of coordination, fainting and dizziness

Severe hypoglycaemia in T2D: hospitalisation and mortality

0.3 per 100 patient-years

Rate of hospitalisation for hypoglycaemia in T2D⁷

days Average length of stay for people with T2D admitted for hypoglycaemia (95% CI: 4.46-5.71)⁸

5.04



19.5% vs. **9%**

All-cause mortality rate over 5 years in people with T2D who had experienced ≥1 episode of severe hypoglycaemia and those who had not respectively (HR: 3.27, 95% CI: 2.29–4.65)⁹

Steps to minimise the risk of hypoglycaemia in your patients



Select an appropriate diet, lifestyle and therapy regimen to treat T2D:

- Balance the glucose-lowering efficacy of therapy with its risk of causing hypoglycaemia¹⁰
- Support the person to aim for an HbA_{1c} level of 53 mmol/mol (7.0%) or an alternative individualised HbA_{1c} target¹⁰

Assess patients for hypoglycaemia at every appointment, particularly those taking medication that increases risk, e.g. insulin or a sulphonylurea¹

Consider each risk factor for hypoglycaemia and whether it can be modified¹

Educate patients about the signs of hypoglycaemia¹

Simplify complex treatment regimens¹

Monitor hospitalised T2D patients for hypoglycaemia¹¹



Low risk GLP-1 receptor agonists



Insulin



Pioglitazone

Medication considerations

Level of risk for hypoglycaemia when used as add-on to metformin:¹²





000

Moderate risk Sulphonylureas

Abbreviations

GLP-1, glucagon-like peptide-1

SGLT2 inhibitors

References

- **1.** Seaquist ER et al (2013) *Diabetes Care* **36**: 1384–95
- 2. Lingvay I (2011) US Endocrinology 7: 95-102
- 3. Almalki MH, Alshahrani F (2016) Front Endocrinol (Lausanne) 7: 32
- Edridge CL et al (2015) *PloS One* **10**: e0126427
 Shi L et al (2014) *Health and Quality of Life Outcomes* **12**: 167
- 6. Mayo Clinic Staff (2015) Diabetic Hypoglycaemia. Available at: http://mayocl.in/2tqdk8w (accessed 05.06.2018)
- Khalid JM et al (2014) Int J Clin Pract Suppl 68: 40–8
 McEwan P et al (2015) BMJ Open Diabetes Res Care 3: e000057
- McEwan P et al (2015) BMJ Open Diabetes Res Care 3: e000057
 Zoungas S et al (2010) N Engl J Med 363: 1410-8
- 10. NICE (2015) Type 2 diabetes in adults: management NG28. Available at: http://bit.ly/1TuAiMx (accessed 05.06.2018)
- **11.** Turchin A et al (2009) *Diabetes Care* **32**: 1153–57
- **12.** Inzucchi SE et al (2015) *Diabetes Care* **38**: 140-9



This infographic was sponsored by the Boehringer Ingelheim and Lilly Diabetes Alliance. OmniaMed SB has provided editorial support. The content has been developed in conjunction with a Programme Steering Committee. Prescribing information and adverse event reporting information can be found at the end of this infographic. Job code: UK/TRJ/00635f(1) Date of preparation: June 2018

Boehringer Ingelheim

CI, confidence interval; DPP-4, dipeptidyl peptidase-4;

HR, hazard ratio; SGLT2, sodium-glucose cotransporter 2;



Prescribing Information (UK) TRAJENTA® Film-coated tablets containing 5 mg linagliptin

Indication: Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as: monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; combination therapy in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control. Dose and Administration: 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin, may be considered to reduce the risk of hypoglycaemia. Renal impairment: no dose adjustment required. Hepatic impairment: pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking. Elderly: no dose adjustment is necessary based on age however, clinical experience in patients > 80 years of age is limited and caution should be exercised when treating this population. Paediatric population: the safety and efficacy of linagliptin in children and adolescents has not yet been established. No data are available. Take the tablets with or without a meal at any time of the day. If a dose is missed, it should be taken as soon as possible but a double dose should not be taken on the same day. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Warnings and Precautions: Linagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin; a dose reduction of the sulphonylurea or insulin may be considered. Acute pancreatitis: In post-marketing experience of linagliptin there have been spontaneously reported adverse reactions of acute pancreatitis. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected. Trajenta should be discontinued; if acute pancreatitis is confirmed, Trajenta should not be restarted. Caution should be exercised in patients with a history of pancreatitis. Bullous pemphigoid: If bullous pemphigoid is suspected, Trajenta should be discontinued. Interactions: Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. It is not an inducer of CYP isozymes. Linagliptin is a P-glycoprotein substrate and inhibits P-glycoprotein mediated transport of digoxin with low potency. Based on these results and in vivo interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates. The risk for clinically meaningful interactions by other medicinal products on linagliptin is low and in clinical studies linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glibenclamide, simvastatin, warfarin, digoxin or oral contraceptives (please refer to Summary of Product Characteristics for information on clinical data). Fertility, pregnancy and lactation: Avoid use during pregnancy. A risk to the breast-fed child cannot be excluded. A decision must be made whether to discontinue breast feeding or to discontinue/abstain from linagliptin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No studies on the effect on human fertility have been conducted for linagliptin. **Undesirable effects:** Adverse reactions reported in patients who received linagliptin 5 mg daily as monotherapy

or as add-on therapies (frequencies identified from pooled analysis of placebo-controlled studies) in clinical trial and from post-marketing experience. The adverse reactions are listed by absolute frequency. Frequencies are defined as very common ($\geq 1/10$), common ($\geq 1/100$ to <1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) or not known (cannot be estimated from the available data). Very common: hypoglycaemia (combination with/add-on to metformin and sulphonylurea). Common: lipase increased (monotherapy; combination with/add-on to metformin; combination with/add-on to metformin and sulphonylurea; combination with/add-on to insulin; combination with/add-on to metformin and empagliflozin). Uncommon: nasopharyngitis (monotherapy; combination with/add-on to metformin; combination with/add-on to insulin); hypersensitivity e.g. bronchial hyperreactivity (monotherapy; combination with/add-on to metformin; combination with/add-on to metformin and sulphonylurea; combination with/add-on to insulin); cough (monotherapy; combination with/add-on to metformin; combination with/add-on to insulin); pancreatitis (combination with/add-on to insulin); constipation (combination with/add-on to insulin); rash (monotherapy; combination with/add-on to metformin; combination with/add-on to metformin and sulphonylurea; combination with/add-on to insulin); amylase increased (combination with/add-on to metformin; combination with/add-on to metformin and sulphonylurea; combination with/add-on to metformin and empagliflozin). Rare: angioedema (monotherapy; combination with/add-on metformin; to combination with/add-on to metformin and sulphonylurea; combination with/add-on to insulin); urticaria (monotherapy; combination with/add-on to metformin; combination with/add-on to metformin and sulphonylurea; combination with/add-on to insulin); amylase increased (monotherapy). Not known: nasopharyngitis (combination with/add-on to metformin and sulphonylurea; combination with/add-on to metformin and empagliflozin); hypersensitivity e.g. bronchial hyperreactivity (combination with/add-on to metformin and empagliflozin); cough (combination with/add-on to metformin and sulphonylurea; combination with/add-on to metformin and empagliflozin); pancreatitis (monotherapy; combination with/add-on to metformin; combination with/add-on to metformin and sulphonylurea; combination with/add-on to metformin and empagliflozin); bullous pemphigoid (monotherapy; combination with/add-on to metformin; combination with/add-on to metformin and sulphonylurea; combination with/add-on to insulin); amylase increased (combination with/add-on to insulin). Prescribers should consult the Summary of Product Characteristics for further information on side effects. Pack sizes and NHS price: 28 tablets £33.26. Legal category: POM. MA number: EU/1/11/707/003. Marketing Authorisation Holder: Boehringer Ingelheim International GmbH, D-55216 Ingelheim am Rhein, Germany. Prescribers should consult the Summary of Product Characteristics for full prescribing information. **Prepared in** April 2017.